Recent interim results from an open-label, first-in-human dose-escalation Phase 1/2 clinical trial (NCT03374657) have shown promising outcomes for patients with Retinitis Punctata Albescens (RPA) and other retinal dystrophies caused by biallelic mutations in the RLBP1 gene. The study evaluated the safety and efficacy of a novel gene therapy utilizing an adeno-associated viral vector (AAV8-RLBP1) delivered via subretinal injection.
The trial included 12 patients with varying stages of disease progression, including those with the characteristic "white dots" fundus appearance typical of RPA. The primary endpoints focused on systemic and ocular safety, as well as the recovery of dark adaptation—a critical functional deficit in these patients.
Results up to three years post-treatment indicated that the AAV8-RLBP1 therapy was generally well-tolerated. While dose-dependent intraocular inflammation was observed, it responded effectively to corticosteroid treatment. Most importantly, the therapy led to significant improvements in dark adaptation kinetics across all dose cohorts. Furthermore, researchers noted the resolution of disease-related retinal deposits, suggesting successful restoration of the visual cycle.
These findings represent a significant milestone in the treatment of RLBP1-associated retinal dystrophies, offering hope for a condition that currently has no approved therapies. By restoring the function of the cellular retinaldehyde-binding protein (CRALBP), this gene therapy addresses the underlying genetic defect, potentially halting disease progression and improving the quality of life for affected individuals.
Medical Disclaimer: This information is for educational purposes only and does not constitute medical advice. Genetic testing and clinical management should be performed by qualified healthcare professionals.